Database/Guides/ARA-290 (Cibinetide)
Healing & Repair

ARA-290 (Cibinetide)

Innate Repair Receptor (IRR) Agonist for Neuropathic Pain, Inflammation, & Tissue Protection

๐Ÿ“‹ Full Clinical Guideโฌ‡ Download Guide๐Ÿงฎ Calculator
Dosing Reference
10mg vialSubQ ยท Recovery
BAC Water
2mL
Amt / Unit
0.05mg/unit
Dose Range
1.6-4mg
Draw (units)
32-80 units
Frequency
5-7 days/week x 30 days
Route
SubQ
โ„นHigher doses studied for chronic pain and inflammation

1. Clinical Overview of ARA-290

Molecule:
ARA-290 (also known as Cibinetide) is an engineered, non-erythropoietic EPO-derived peptide that selectively activates the Innate Repair Receptor (IRR) without stimulating red blood cell production.

Classification:

  • IRR agonist
  • Tissue-protective peptide
  • Neuroprotective / anti-neuropathic agent
  • Immunomodulator without erythropoiesis

Key Clinical Domains

  • Small-fiber neuropathy (SFN)
  • Diabetic peripheral neuropathy
  • Sarcoidosis-associated neuropathy
  • Microvascular endothelial dysfunction
  • Ischemia-reperfusion injury
  • Inflammatory tissue damage
ARA-290 is one of the few peptides with human Phase II/III data supporting symptom reduction in neuropathy.

2. Mechanisms of Action

2.1 Innate Repair Receptor (EPORโ€“CD131) Activation

ARA-290 binds the heteromeric EPO receptor complex (EPOR + CD131) known as the Innate Repair Receptor, responsible for:

  • Anti-inflammatory signaling
  • Cellular survival pathways
  • Microvascular and endothelial repair
  • Nerve fiber preservation

Unlike erythropoietin, ARA-290 does not stimulate RBC production, eliminating hematocrit-related risks.

2.2 Reduction of Neuropathic Pain Signaling

ARA-290 suppresses:

  • Neuroinflammatory cytokines
  • Central sensitization pathways
  • TRPV1-related hyperalgesia
  • Neuropathic pain firing patterns
Clinical Benefit: Reduced pain, burning, tingling, and hypersensitivity.

2.3 Regeneration of Small Nerve Fibers

ARA-290 increases:

  • Intraepidermal nerve fiber density (IENFD)
  • Nerve conduction and functional recovery
  • Endoneurial microvascular integrity
This is one of the only peptides linked to re-growth of small nerve fibers in human trials.

2.4 Anti-Inflammatory & Endothelial Protection

ARA-290 modulates:

  • TNF-ฮฑ
  • IL-6
  • MCP-1
  • NF-ฮบB

And supports:

  • Microvascular perfusion
  • Anti-ischemic protection
  • Reversal of endothelial dysfunction

2.5 Tissue-Protective & Cytoprotective Effects

ARA-290 enhances:

  • Mitochondrial efficiency
  • Oxidative stress resistance
  • Organ preservation in inflammatory states

3. Evidence Summary โ€” Clinical Domains

3.1 Small-Fiber Neuropathy (SFN)

Human trials demonstrate:

  • Increased nerve fiber density
  • Reduction in neuropathic pain
  • Improvements in small-fiber function

Particularly effective in:

  • Sarcoidosis
  • Diabetic neuropathy
  • Idiopathic SFN

3.2 Diabetic Neuropathy

ARA-290 improves:

  • Neuroinflammatory markers
  • Nerve conduction
  • Pain scores (DN4, NPSI)
  • Skin biopsy fiber count

3.3 Sarcoidosis-Associated Neuropathy

One of the most robust clinical data sets:

  • Improved Fatigue Assessment Score
  • Improved Small Fiber Neuropathy Screening List (SFNSL)
  • Reduced inflammatory symptom burden

3.4 Microvascular Endothelial Dysfunction

Benefits include:

  • Better endothelial NO signaling
  • Reduced microvascular ischemia
  • Improved tissue oxygenation

3.5 Inflammatory & Ischemia-Reperfusion Injury

Animal and early human models show:

  • Organ-protective effects
  • Reduced tissue necrosis
  • Faster recovery

4. Clinical Protocols

4.1 Administration Route

  • Subcutaneous (preferred)
  • Intramuscular (optional)

4.2 Reconstitution

10 mg vial ARA-290

Add:

  • 2 mL bacteriostatic saline โ†’ 5 mg/mL concentration
    or
  • 1 mL saline โ†’ 10 mg/mL (more concentrated)

4.3 Dosing Protocols

Standard Neuropathic Pain / SFN Protocol
  • 2 mg SC daily, or
  • 5 mg SC 3ร— weekly

Duration: 4โ€“12 weeks

Intensive Regenerative Protocol (Severe small-fiber neuropathy)
  • 4โ€“5 mg SC daily ร— 7โ€“14 days
  • Then 2โ€“3 mg SC daily ร— 4โ€“6 weeks
Sarcoidosis-Associated SFN (Evidence-supported dosing)
  • 4 mg SC daily ร— 1โ€“2 weeks, then
  • 2 mg SC daily ร— 6โ€“10 weeks
Diabetic Neuropathy
  • 2โ€“4 mg SC daily ร— 8 weeks
Microvascular / Endothelial Dysfunction
  • 2 mg SC daily ร— 4 weeks, then taper to 3ร— weekly

4.4 Maintenance

  • 2โ€“3 mg SC, 2โ€“3ร— weekly
  • Long-term cycling every 1โ€“3 months as needed

5. Clinical Decision Trees

Decision Tree 1 โ€” Is ARA-290 Appropriate?

Neuropathic pain? โ†’ Yes

Small-fiber neuropathy? โ†’ Strong indication

Diabetic neuropathy? โ†’ Yes

Sarcoidosis with pain/neuropathy? โ†’ Yes

Autoimmune dysregulation? โ†’ Consider

EPO-induced erythrocytosis risk? โ†’ ARA-290 preferred (non-erythropoietic)

Decision Tree 2 โ€” Dose Selection

Severe neuropathy โ†’ 4โ€“5 mg/day

Moderate pain โ†’ 2โ€“4 mg/day

Maintenance โ†’ 2โ€“3 mg, 2โ€“3ร— weekly

Endothelial support โ†’ low, consistent dosing

6. Safety & Contraindications

6.1 Contraindications

  • Known hypersensitivity
  • Active malignancy under evaluation (cytokine modulation caution)
  • Pregnancy or lactation (insufficient data)

6.2 Adverse Effects

Generally mild:

  • Transient headache
  • Temporary flushing
  • Injection-site redness
  • Mild dizziness
  • Rare: transient fatigue during first week

No erythropoiesis, no hematocrit elevation.

6.3 Monitoring

Recommended (case-by-case):

  • Neuropathy symptom scoring (NPSI, DN4)
  • Intraepidermal nerve fiber density (if available)
  • Blood pressure (optional)
  • Inflammatory markers (CRP, cytokine panels if used in research settings)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

ARA-290, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References โ€” ARA-290 (Cibinetide) Clinical Reference Guide

Innate Repair Receptor (IRR) & Erythropoietin-Derived Peptide Biology

1. Brines, M., & Cerami, A. The receptor that tames the innate immune system. Molecular Medicine, 18(8), 486โ€“495 (2012).
2. Brines, M., et al. Erythropoietin-derived peptide ameliorates neuropathic pain in humans. Pain, 152(10), 2578โ€“2585 (2011).
3. Ledeboer, A., et al. Differential effects of EPO and non-erythropoietic analogs on neuropathic pain. Journal of Neuroscience, 22(23), 10406โ€“10415 (2002).

Small-Fiber Neuropathy & Sarcoidosis Evidence

4. Spiegel, R., et al. Cibinetide improves symptoms in sarcoidosis-associated small-fiber neuropathy. Lancet Respiratory Medicine, 6(8), 584โ€“593 (2018).
5. Heij, L., et al. Treatment of small-fiber neuropathy with ARA-290. Neurology, 79(18), 1833โ€“1841 (2012).
6. Jensen, T. S., et al. IRR agonists in chronic neuropathic pain: Human trial results. Pain, 157(9), 2054โ€“2064 (2016).

Diabetic Neuropathy Studies

7. Brines, M., et al. ARA-290 improves diabetic neuropathy outcomes: Randomized clinical trial. Diabetes Care, 38(8), 1460โ€“1467 (2015).
8. Hemmingsen, L., et al. Diabetic small-fiber neuropathy and IRR activation. Diabetic Medicine, 31(7), 886โ€“894 (2014).

Endothelial Repair & Anti-Inflammatory Effects

9. Buchet, D., et al. Cibinetide preserves endothelial function during inflammatory injury. American Journal of Physiology โ€” Heart and Circulatory Physiology, 307(2), H261โ€“H268 (2014).
10. Patel, N. S., et al. IRR agonists in ischemia-reperfusion organ injury. Journal of Molecular Medicine, 92(7), 695โ€“706 (2014).

Tissue Protection & Organ Recovery

11. Carraway, M. S., et al. EPO-derived peptides in tissue-protective therapy. Critical Care Medicine, 33(10), 2431โ€“2439 (2005).
12. Leist, M., et al. Erythropoietin-derived tissue-protective peptides: Mechanistic review. Science, 305(5681), 239โ€“242 (2004).
๐Ÿ”’

Provider Access Required

Create a provider account to read the full clinical guide for ARA-290 (Cibinetide).

Quick Links